Evaluation of Multimodal Imaging Biomarkers of Prostate Cancer
Abstract
The goals of the proposed studies are to: i) use imaging methods to non-invasively assess the temporal relationship between castration resistant prostate cancer (CRPC) growth, androgen receptor (AR) levels, angiogenesis, hypoxia, and translocator protein (TSPO) levels and ii) use imaging to temporally direct pathological examination of tissue in order to enhance the elucidation of mechanistic aspects of CRPC progression, specifically the involvement of HIF-1alpha and NF-kappaB, two pathways that increase AR activity during progression to CRPC. As described in the statement of work, the first year of this award focused on implementation and optimization of the imaging methods in the Pten / p53 double null mutant mouse model. Towards that end, we have successfully optimized anatomic MRI and dynamic contrast enhanced (DCE) MRI methods, in orthotopic tumors within the Pten/p53 mouse model, to assess tumor volume, track growth and tumor angiogenesis. In regards to PET imaging, we have completed the synthesis, purification and stability verification of the [18F]- fluoro-5alpha-dihydrotestosterone (FDHT) radiotracer, which will be used to assess AR levels in these mice. We have also acquired dynamic FDHT PET data in control mice and those bearing prostate cancers. At this stage in the project we have finalized the MRI and PET acquisition protocols that will be utilized in the second year of the award.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2013
- Accession Number
- ADA593303
Entities
People
- Christopher C. Quarles
Organizations
- Vanderbilt University Medical Center